The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of YM155, selective survivin suppressant in combination with elrotnib in patients with EGFR-mutant advanced non-small cell lung cancer.
 
Toshio Shimizu
Research Funding - Astellas Pharma (Inst); Novartis (Inst)
 
Kazuto Nishio
No Relationships to Disclose
 
Kazuko Sakai
No Relationships to Disclose
 
Hidetoshi Hayashi
No Relationships to Disclose
 
Kunio Okamoto
No Relationships to Disclose
 
Masayuki Takeda
No Relationships to Disclose
 
Tsutomu Iwasa
No Relationships to Disclose
 
Kaoru Tanaka
No Relationships to Disclose
 
Koji Aoyama
Employment - Astellas Pharma
 
Maiko Morishita
Employment - Astellas Pharma
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Chugai Pharma
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst)